GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability and accessibility, today ...

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s ...

HONG KONG SAR - Media OutReach Newswire - 30 October 2024 - AIM Vaccine (06660.HK), the leader in Chinese mRNA vaccines, announced on 30th October that mRNA respiratory ...

GlaxoSmithKline Pharmaceuticals Limited reported that its revenue from operations in the second quarter of FY25 crossed Rs 1000 crore, up 5 per cent Year-on-Year. Profit After Tax (PAT) for the ...

Revenue from operations rose to Rs 1,010 crore for the September quarter compared with Rs 957 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing.

GlaxoSmithKline Pharmaceuticals on Tuesday reported a 16 per cent year-on-year increase in its consolidated net profit to Rs 252 crore in the September quarter, aided by robust sales across segments.

GlaxoSmithKline Pharmaceuticals reports a 16% jump in Q2 net profit to Rs 252 crore, driven by strong sales across segments.

Founded in 1715, GSK was originally known as GlaxoSmithKline ... rash caused by the reactivation of the varicella-zoster virus. This vaccine targets 50-year-olds, older adults, and ...